There are multiple interventions designed for the treatment of obesity, including various surgical procedures. Still, the fundamental approach to obesity, no matter what other interventional therapy is provided, includes diet, exercise, and behavior management. Additionally, pharmacologic interventions have a long history of moderate success and should be part of the multidimensional approach to the treatment of the obese patient. The goals of medical weight management should be (1) to reduce central abdominal fat stores; (2) to prevent, eliminate, or improve obesity-related complications; (3) to improve quality of life; and (4) to reduce mortality in the obese and overweight populations with comorbidities.
- Binge Eating
- Glycemic Index
- Excess Body Weight
- Gastric Inhibitory Polypeptide
- Glycemic Load
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, access via your institution.
Tax calculation will be finalised at checkout
Purchases are for personal use onlyLearn about institutional subscriptions
Marti A, Marcos A, Martínez JA. Obesity and immune function relationships. Obes Rev. 2001;2:131–40.
Warnberg J, Morena LA, Mesana MI, Marcos A, Group A. Inflammatory mediators in overweight and obese Spanish adolescents. The AVENA Study. Int J Obes Relat Metab Disord. 2004;28 Suppl 3:S59–63.
Warnberg J, Nova E, Moreno LA, et al. Inflammatory proteins are related to total and abdominal adiposity in a healthy adolescent population: the AVENA Study. Am J Clin Nutr. 2006;84:505–12.
Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Low-grade systemic inflammation in overweight children. Pediatrics. 2001;107:E13.
Overweight and Obesity. http://www.cdc.gov/women/natstat/overwght.htm. Accessed 21 Mar 2010.
Weight-Control Information Network, NIDDK. Understanding adult obesity. http://win.niddk.nih.gov/publications/understanding.htm. Accessed 21 Mar 2010.
Center for Disease Control. Obesity and overweight for professionals: health consequences. http://www.cdc.gov/obesity/causes/health.html. Accessed 19 Mar 2010.
Stern JS. Preface. In: Thomas P, editor. Weighing the options: criteria for evaluating weight management programs. Washington DC: Institutes of Medicine, National Academic Press; 1995. p. 7–10.
National Heart, Lung and Blood Institute. The practical guide: identification, evaluation, and treatment of overweight and obesity in adults. http://www.nhlbi.nih.gov/guidelines/obesity/prctgd_c.pdf. Accessed 19 Mar 2010.
U.S. Department of Health and Human Services and U.S. Department of Agriculture. Dietary guidelines for Americans 2005. http://www.health.gov/dietaryguidelines/dga2005/document/default.htm. Accessed 19 Mar 2010.
National Heart, Lung and Blood Institute, Washington DC. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. http://www.nhlbi.nih.gov/guidelines/obesity/ob_gdlns.pdf. Accessed 19 Mar 2010.
Dwyer JT, Melanson K, Faucon LN. Dietary treatment of obesity. http://www.endotext.org/obesity/obesity18/obesity18.htm. Accessed 20 Mar 2010.
Optifast Weight Loss Program. Optifast the serious solution for weight loss. http://www.optifast.com/Pages/medically_monitored_weight_loss.aspx?s_kwcid=TC|6957|optifast||S||3236986565&gclid=CMe945P-zKACFRKfnAod4hC50A. Accessed 19 Mar 2010.
Medifast Weight Loss Program. http://www.medifast.com. Accessed 19 Mar 2010.
NutriMed Weight Loss Products by Robard. http://www.robard.com/ProgramsProducts/NMProduct/NutriMedProduct.aspx. Accessed 19 Mar 2010.
HMR (Health Management Resources). http://www.ihmonline.com/products_index.aspx. Accessed 19 Mar 2010.
The Cambridge Diet. http://www.cambridgediet.net/physicians.htm. Accessed 19 Mar 2010.
HealthOne. http://www.myhealthone.com/products.html. Accessed 19 Mar 2010.
The HCG Program. http://www.hcgdietplan.org/contact.html. Accessed 19 Mar 2010.
National Institute of Diabetes and Digestive and Kidney Diseases. Very low calorie diets. http://win.niddk.nih.gov/publications/low_calorie.htm. Accessed 19 Mar 2010.
Anderson JW, Grant L, Gotthelf L, et al. Weight loss and long-term follow-up of severely obese individuals treated with an intense behavioral program. Int J Obes. 2007;31:488–93.
Gilden Tsai A, Wadden T. The evolution of very low calorie diets: an up-date and meta-analysis. Obesity. 2006;14:1283–93.
Saris WH. Very-low calorie diets and sustained weight loss. Obes Res. 2001;9:295S–301.
Beals JK. Very-low-calorie diet before bariatric surgery reduces risk in superobese patients. http://www.medscape.org/viewarticle/582071. Accessed 21 Mar 2010.
Lewis MC, Phillips ML, Slavotinek JP, et al. Change in liver size and fat content after treatment with Optifast very low calorie diet. Obes Surg. 2006;16:697–701.
de Toledo Triffoni-Melo A, Dick-de-Paula I, Portari GV, Jordao AA, Garcia Chiarello, Diez-Garcia RW. Short-term carbohydrate-restricted diet for weight loss on severely obese women. Obes Surg. 2011;21(8):1194–202. Epub ahead of print.
Huerta S, Li Z, Anthony T, et al. Feasibility of a supervised inpatient low-calorie diet program for massive weight loss prior to RYGB in superobese patients. Obes Surg. 2010;20:173–80.
Plodkowski RA, St Jeor ST. Medical nutrition therapy for the treatment of obesity. Endocrinol Metab Clin North Am. 2003;32:935–65.
Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med. 1997;336:1117–24.
Hollis JF, Gullion CM, Stephens VJ, et al. Weight loss during the intense intervention phase of the weight loss maintenance trial. Am J Prev Med. 2008;35:118–26.
Svetkey LP, Stevens VJ, Brantley PJ, et al. Comparison of strategies for sustained weight loss: the weight loss maintenance randomized controlled trial. JAMA. 2008;12:1139–48.
Weight Watchers. http://www.weightwatchers.com/templates/marketing/Landing_1col_nonav.aspx?PageId=1163821. Accessed 21 Mar 2010.
Jenny Craig Weight Loss Program. http://www.jennycraig.com. Accessed 21 Mar 2010.
Nutrisystem. http://www.nutrisystem.com. Accessed 21 Mar 2010.
LA Weight Loss. http://www.la-weightloss.com/default.aspx. Accessed 21 Mar 2010.
Levine MJ, Jones JM, Lineback DR. Low-carbohydrate diets: assessing the science and knowledge gaps, summary of an ILSI North America Workshop. J Am Diet Assoc. 2006;106(12):2086–94.
The Atkins Diet. http://www.atkins.com/Homepage.aspx. Accessed 21 Mar 2010.
Sears B. The Zone. Los Angeles, CA: Regan Books; 1995.
Agastston A. The South beach diet. New York City, NY: St. Martin’s Griffin; 2005.
Eades MR. Protein power. New York City, NY: Bantam Books; 1997.
Brand-Miller J, Foster-Powell K, McMillan-Price J. The low GI diet revolution: the definitive science-based weight loss plan. Cambridge, MA: Da Capo; 2004.
Sugar Busters. http://sugarbusters.com. Accessed 19 Mar 2010.
Jenkins D, Wolever T, Taylor R, et al. Glycemic Index of foods: a physiological basis for carbohydrate exchange. Am J Clin Nutr. 1981;34:362–6.
Brouns F, Bjorck I, Frayn KN, et al. Glycaemic index methodology. Nutr Res Rev. 2005;18:145–71.
Ludwig DS. The glycemic index: physiological mechanisms relating to obesity, diabetes, and cardiovascular disease. JAMA. 2002;287:2414–23.
St Jeor ST, Howard BV, Prewitt E, et al. Dietary protein and weight reduction. A statement for healthcare professionals from the nutrition committee of the council on nutrition, physical activity, and metabolism of the American Heart Association. Circulation. 2001;104:1869–74.
Brierly D, Carlson M, Donnelly A, et al. 1967: the Stillman diet. (History Of Diets, Part 12). (protein diet) (Brief Article). Men’s Fitness. Weider Publications LLC. 2003. Retrieved December 24, 2012 from HighBeam Research: http://www.highbeam.com/doc/1G1-102140891.html
Stern JS. Obesity: food intake. In: Bray GA, editor. Office management of obesity. Philadelphia, PA: Elsevier; 2004.
Stern JS, Hirsch J, Blair SN, et al. Weighing the options: criteria for evaluating weight-management programs. The Committee to develop criteria for evaluating the outcomes of approaches to prevent and treat obesity. Obes Res. 1995;3:591–604.
Foreyt JP, Salas-Salvado J, Caballero B, et al. Weight-reducing diets: are there any differences? Nutr Rev. 2009;67:S99–101.
Jéquier E, Bray GA. Low-fat diets are preferred. Am J Med. 2002;113(Suppl):41S–6.
Willett WC, Leibel RL. Dietary fat is not a major determinant of body fat. Am J Med. 2002; 113(Suppl): 47S–59.
Freedman MR, King J, Kennedy E. Popular diets: a scientific review. Obes Res. 2001;9(Suppl):1S–40.
Skov AR, Toubro S, Rønn B, Holm L, Astrup A. Randomized trial of protein vs. carbohydrate in ad libitum fat reduced diet for the treatment of obesity. Int J Obes Relat Metab Disord. 1999;23:528–36.
Brehm BJ, Seeley RJ, Daniels SR, D’Alessio DA. A randomized trial comparing a very low carbohydrate diet and a calorie-restricted low fat diet on body weight and cardiovascular risk factors in healthy women. J Clin Endocrinol Metab. 2003;88:1617–23.
Foster GD, Wyatt HR, Hill JO, et al. A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med. 2003;348:2082–90.
Samaha FF, Iqbal N, Seshadri P, et al. A low-carbohydrate as compared with a low-fat diet in severe obesity. N Engl J Med. 2003;348:2074–81.
Yancy Jr WS, Olsen MK, Guyton JR, Bakst RP, Westman EC. A low-carbohydrate ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia: a randomized, controlled trial. Ann Intern Med. 2004;140:769–77.
Volek J, Sharman M, Gómez A, et al. Comparison of energy-restricted very low-carbohydrate and low-fat diets on weight loss and body composition in overweight men and women. Nutr Metab (Lond). 2004;1:13.
Due A, Toubro S, Skov AR, Astrup A. Effect of normal-fat diets, either medium or high in protein, on body weight in overweight subjects: a randomised 1-year trial. Int J Obes Relat Metab Disord. 2004;28:1283–90.
Gardner CD, Kiazand A, Alhassan S, et al. Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women: the A to Z Weight Loss Study: a randomized trial. JAMA. 2007;297:969–77. Erratum, JAMA. 2007;298:178.
Shai I, Schwarzfuchs D, Henkin Y, et al. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med. 2008;359:229–41.
Noakes M, Keough JB, Foster PR, Clifton PM. Effect of an energy-restricted, high-protein, low-fat diet relative to a conventional low-fat, high-carbohydrate diet on weight loss, body composition, nutritional status, and markers of cardiovascular health in obese women. Am J Clin Nutr. 2005;81:1298–306.
McLaughlin T, Carter S, Lamendola C, et al. Effects of moderate variations in macronutrient composition on weight loss and reduction in cardiovascular disease risk in obese, insulin-resistant adults. Am J Clin Nutr. 2006;84:813–21.
McMillan-Price J, Petocz P, Atkinson F, et al. Comparison of 4 diets of varying glycemic load on weight loss and cardiovascular risk reduction in overweight and obese young adults: a randomized controlled trial. Arch Intern Med. 2006;166:1466–75.
Das SK, Gilhooly CH, Golden JK, et al. Long-term effects of 2 energy-restricted diets differing in glycemic load on dietary adherence, body composition, and metabolism in CALERIE: a 1-y randomized controlled trial. Am J Clin Nutr. 2007;85:1023–30.
Lecheminant JD, Gibson CA, Sullivan DK, et al. Comparison of a low carbohydrate and low fat diet for weight maintenance in overweight or obese adults enrolled in a clinical weight management program. Nutr J. 2007;6:36.
Stern L, Iqbal N, Seshadri P, et al. The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: one-year follow-up of a randomized trial. Ann Intern Med. 2004;140:778–85.
Dansinger ML, Gleason JA, Griffith JL, Selker JP, Schaefer EJ. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA. 2005;293:43–53.
Luscombe-Marsh ND, Noakes M, Wittert GA, Keough JB, Foster P, Clifton PM. Carbohydrate restricted diets high in either monounsaturated fat or protein are equally effective in promoting fat loss and improving blood lipids. Am J Clin Nutr. 2005;81:762–72.
Keogh JB, Luscombe-Marsh ND, Noakes M, Wittert GA, Clifton PM. Long-term weight maintenance and cardiovascular risk factors are not different following weight loss on carbohydrate-restricted diets high in either monounsaturated fat or protein in obese hyperinsulinemic men and women. Br J Nutr. 2007;97:405–10.
Sacks FM, Bray GA, Carey VJ, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med. 2009;360: 859–73.
Vetter ML, Iqbal N, Dalton-Bakes C, et al. Long-term effects of low-carbohydrate versus low-fat diets in obese persons. Ann Intern Med. 2010;152:334–5.
National Institute of Health Medline Plus. Diets. http://www.nlm.nih.gov/medlineplus/diets.html. Accessed 20 Mar 2010.
James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial: STORM Study Group: sibutramine trial of obesity reduction and maintenance. Lancet. 2000;356:2119–25.
Torgerson JS, Hauptman J, Boldrin MN, et al. Xenical in the prevention of diabetes in obese subjects (XENDOS) study: randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004; 27:155–61.
Van Gaasl LF, Rissanen AM, Scheen AJ, et al. Effects of the cannabinoid-1 receptor antagonist blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO_Europe study. Lancet. 2005;365: 1389–92.
Nair RP, Ren J. Pharmacotherapy of obesity—benefit, bias and hyperbole. Curr Med Chem. 2009;16:1888–97.
Haddock CK, Polson WS, Foreyt JP, et al. Effectiveness of Medifast supplements combined with obesity pharmacotherapy: a clinical program evaluation. Eat Weight Disord. 2008;13:95–101.
Luque CA, Rey JA. Sibutramine: a serotonin-norepinephrine-reuptake-inhibitor for the treatment of obesity. Ann Pharmacother. 1999;33:968–78.
Hansen DL, Toubro S, Stock MJ, et al. The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. Int J Obes. 1999;23:1016–24.
Bray GA, Blackburn GL, Ferguson JM, et al. Sibutramine produces dose-related weight loss. Obes Res. 1999;7:189.
Rucker D, Padwal R, Li SK, et al. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ. 2007;335:1194.
European Medicines Association. Press release. http://www.ema.europa.eu/pdfs/human/press/pr/75243109en.pdf. Accessed 21 Mar 2010.
Torp-Pederson C, Caterson I, Coutinho W, et al. Cardiovascular response to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J. 2007;28:2915–23.
Maggioni AP, Caterson I, Coutinho W, et al. Tolerability of sibutramine during a 6-week period in high-risk patients with cardiovascular disease and/or diabetes: a preliminary analysis of the sibutramine cardiovascular outcomes (SCOUT) trial. J Cardiovasc Pharmacol. 2008;52:393–402.
Food and Drug Administration. Follow-up to the November 2009 early communication about an ongoing safety review of sibutramine, marketed as Meridia. http://www.fda.gov/Drugs/DrugSafety/Postmarket DrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm198206.htm. Accessed 21 Mar 2010.
Meridia (sibutramine): Market Withdrawal Due to Risk of Serious Cardiovascular Events. http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm228830.htm. Accessed 22 Dec 2012.
Colman E. Anorectics on trial: a half century of federal regulation of prescription appetite suppressants. Ann Intern Med. 2005;143:380–5.
Drent ML, van der Veen EA. Lipase inhibition: a novel concept in the treatment of obesity. Int J Obes. 1993;17:241–4.
Tolpak H, Zieglar O, Keller U, et al. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced energy diet: early response to treatment predicts weight maintenance. Diabetes Obes Metab. 2005;7:699–708.
Goldstein DJ, Rampey AHJ, Enas GG, et al. Fluoxetine: a randomized clinical trial in the treatment of obesity. Int J Obes Relat Metab Disord. 1994;18(3):129–35.
Wadden TA, Bartlett SJ, Foster GD, et al. Sertraline and relapse prevention training following treatment by very-low-calorie diet: a controlled clinical trial. Obes Res. 1995;3:549–57.
Gadde KM, Parker CB, Maner LG, et al. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obes Res. 2001;9:544–51.
FDA approves Belviq to treat some overweight or obese adults. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm309993.htm. Accessed 22 Dec 2012.
Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management. New England Journal of Medicine. 2010;363(3):245–56.
Fidler MC, Sanchez M, Raether B, et al. A One-Year Randomized Trial of Lorcaserin for Weight Loss in Obese and Overweight Adults: The BLOSSOM Trial. Journal of Clinical Endocrinology & Metabolism. 2011;96(10):3067–77.
O’Neil PM, Smith SR, Weissman NJ, et al. Randomized Placebo-Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM-DM Study. Obesity. 2012;20(7):1426–36.
Bray GA, Hollander P, Klein S, et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res. 2003;11:722.
Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005;142:532.
Gadde KM, Franciscy DM, Wagner 2nd HR, Krishnan KR. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA. 2003;289:1820.
Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.
Ratner RE, Dickey R, Fineman M, et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med. 2004;21:1204–12.
Maggs D, Shen L, Strobel S, et al. Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis. Metabolism. 2003;52: 1638–42.
Poon T, Nelson P, Shen L, et al. Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes; a dose-ranging study. Diabetes Technol Ther. 2005;7:466–7.
Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes; a 26-week randomized, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39–47.
Astrup A, Rossner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomized, double-blind, placebo-controlled study. Lancet 2009;374:1606–16.
Madsbad S. Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonist (incretin mimetics)—preclinical and clinical results. Best Pract res Clin Endocrinol Metabol. 2009;23:463–77.
Victoza (loraglutide). http://www.theonlineclinic.co.uk/liraglutide-victoza.asp Accessed 22 Dec 2012.
Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME, Niskanen L, Rasmussen MF, Rissanen A, Rössner S, Savolainen MJ, Van Gaal L; NN8022–1807 Investigators. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond). 2012;36(6):843–54. doi: 10.1038/ijo.2011.158. Epub 2011 Aug 16. Erratum in: Int J Obes (Lond). 2012;36(6):890. http://www.ncbi.nlm.nih.gov/pubmed/21844879.
Ioannides-Demos LL, Piccenna L, McNeil JJ. Pharmacotherapies for Obesity: Past, Current, and Future Therapies. Journal of Obesity. 2011;2011:1–18.
Rodgers RJTM, Wilding JPH. Anti-obesity drugs: past, present and future. Disease Models and Mechanisms. 2012;5:621–26.
Colman EGJ, Roberts M, Egan A, Weaver J and Rosebraugh C. The FDA’s Assessment of Two Drugs for Chronic Weight Management. N Engl J Med. 2012;367(17):1577–79.
FDA approves weight management drug Qsymia. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312468.htm Accessed 22 Dec 2012.
Saper RB, Eisenberg DM, Phillips RS. Common dietary supplements for weight loss. Am Fam Physician. 2004;70:1731.
Cohen PA, McCormick D, Casey C, et al. Imported compounded diet pill use among Brazilian women immigrants in the United States. J Immigr Minor Health. 2007;11:229–36.
FDA Alert. FDA warns consumers about Brazilian diet pills found to contain active drug ingredients: Emagrece Sim and Herbathin dietary supplements may be harmful. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108578.htm. Accessed 19 Mar 2010.
Curioni C, Andre C. Rimonabant for overweight or obesity. Cochrane Database Syst Rev. 2006;(4):CD006162.
Bello NT, Zahner MR. Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity. Curr Opin Investig Drugs. 2009;10:1105–16.
Drogrell SA. Tesofensine—a novel potent weight loss medicine. Evaluation of: Astrup A, Bruen L, Jensen TJ, Kroupstrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomized, double-blind, placebo-controlled trial. Lancet 2008;372:1906–1913. Expert Opin Investig Drugs. 2009;18:1043–6.
Padwal R. Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity. Curr Opin Investig Drugs. 2009;10:1117–25.
F.D.A. declines to approve diet drug. http://www.nytimes.com/2011/02/02/business/02drug.html. Accessed 24 Dec 2012.
Contrave. http://www.orexigen.com/product-candidates/contrave.html. Accessed 22 Dec 2012.
Arrone LJ, Tonstad S, Moreno M, et al. A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study. Int J Obes. 2010;34(5):919–35.
Addy C, Jumes R, Rosko K, et al. Pharmacokinetics, safety, and tolerability of phentermine in healthy participants receiving taranabant, a novel cannabinoid-1 receptor (CB1R) inverse agonist. J Clin Pharmacol. 2009;49:1228–38.
Heymsfield SB, Greenberg AS, Fujioka K, et al. Recombinant leptin for weight loss in obese and lean adults. A randomized, controlled, dose-escalation trial. JAMA. 1999;282:1567–8.
Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med. 2003;349:941–8.
Pfafffenger RS, Hyde RT, Wing AL, Hsieh CC. Physical activity, all cause mortality, and longevity of college alumni. N Engl J Med. 1986;3:605–13.
Mansen JE, Hu FB, Rich-Edwards JW, Colditz GA, Stampler MJ, Wollett WC. A prospective study of walking as compared with vigorous exercise in the prevention of coronary artery disease in women. N Engl J Med. 1991;341:650–8.
Blair SN, Kohl III, Barlow CE, et al. Relationship between low cardiorespiratory fitness and mortality in normal-weight, overweight, and obese men. JAMA. 1995;273:1093–8.
National Institute of health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults—the evidence report. Obes Res. 1998;6 Suppl 2:51S–209.
Barlow CE, Kohl HW, Gibbons LW, Blair SN. Physical activity, mortality and obesity. Int J Obes. 1995;19:S41–5.
Tatarrani PA, Ravussin E. Energy metabolism and obesity. In: Wadden TA, Stunkard AJ, editors. Handbook of obesity treatment. New York, NY: Guilford; 2002.
Rennie KL, Wareham NJ. The validation of physical activity instruments for measuring energy expenditure: problems and pitfalls. Public Health Nutr. 1998;1:265–72.
Health and Safety Executive. Health survey for England 2003. http://www.dh.gov.uk/en/Publicationsandstatistics/PublishedSurvey/HealthSurveyForEngland/index.htm.
Wareham N. Physical activity and obesity prevention. Obes Rev. 2007;8 Suppl 1:109–14.
Donnely JE, Hill JO, Jacobsen DJ, et al. Effects of a very-low calorie diet and physical-training regimens on body composition and resting metabolic rate in obese females. Am J Clin Nutr. 1991;54:56–61.
Pate RR, Pratt M, Blair SN, et al. Physical activity and public health. A recommendation from the centers for disease control and prevention and the American College of Sports Medicine. JAMA. 1995;273:402–7.
Donnelly JE, Smith B, Jacobsen DJ, et al. The role of exercise for weight loss and maintenance. Best Pract Res Clin Gastroentrol. 2004;18:1009–29.
Jakcicic JM, Clark K, Coleman E, et al. American College of Sports Medicine position stand. Appropriate intervention strategies for weight loss and prevention for regain for adults. Med Sic Sports Exerc. 2001;33:2145–56.
Institute of Medicine. Dietary reference intake for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein and amino acids. Washington, DC: National Academic Press; 2002. p. 3–5.
Katzmarzyk PT, Janssen I, Ardern CI. Physical inactivity, excess adiposity and premature mortality. Obes Rev. 2003;4:257–90.
Kelm ML, Wing RR, McGuire MT, et al. A descriptive study of individuals successful at long-term weight maintenance of substantial weight loss. Am J Clin Nutr. 1997;66:239–46.
Haskell WL, Lee I-M, Pate RR, et al. Physical activity and public health. Updated recommendation for adults form the American College of Sports Medicine and the American Heart Association. Med Sci Sports Exerc. 2007;39(8):1423–34.
Johannsen DL, Redman LM, Ravussin E. The role of physical activity in maintaining a reduced weight. Nutrition. 2007;9(6):463–71.
Pavlou NK, Krey S, Steffe WP. Exercise as an adjunct to weight loss and maintenance in moderately obese subjects. Am J Clin Nutr. 1989;45(5supp1):1115–23.
Jakicic JM, Winters C, Lang W, Wing RR. Effects of intermittent exercise and use of home exercise equipment on adherence, weight loss, and fitness in overweight woman, a randomized trial. JAMA. 1999;282:1554–60.
Slentz CA, Duscha BD, Johnson JL, et al. Effects of the amount of exercise on body weight, body composition, and measures of central obesity. STRRIDE—a randomized controlled trial. JAMA. 2007;297:2081–91.
Jeffrey RW, Wing RR, Sherwood NE, et al. Physical activity and weight loss: does prescribing higher physical activity goals improve outcome. Am J Clin Nutr. 2007;85:954–9.
Bruun JM, Helge JW, Richelsen B, Stallknecht B. Diet and exercise reduce low-grade inflammation and macrophage infiltration in adipose tissue but not in skeletal muscle in severely obese subjects. Am J Physiol Endocrinol Metab. 2006;209:E961–7.
Shaw KA, Gennat HC, O’Rourke P, Del Mar C. Exercise for overweight and obesity. The Cochrane Lib. 2009;1:1–104.
Wadden TA, Foster GD. Behavioral treatment of obesity. Med Clin North Am. 2000;84:441–57.
Ravussin E, Lillioja S, Knowler WC, et al. Reduced rate of energy expenditure as a risk factor for body weight gain. N Engl J Med. 1988;318:462–8.
Kanfer FH. Self-monitoring; methodological imitations and clinical applications. J Consult Clin Psychol. 1970;35:148–52.
Carels RA, Darby LA, Rydin S, et al. The relationship between self-monitoring, outcome experiences, difficulties with eating and exercise, and physical activity and weight loss treatment outcomes. Ann Behav Med. 2005;30:182–90.
Johnston CA, Tyler C, Foreyt JP, et al. Behavioral management of obesity. Nutrition. 2007;9:448–53.
Berkel LA, Poston WS, Reeves RS, et al. Behavioral interventions and obesity. J Am Diet Assoc. 2005;105 Suppl 1:S35–43.
Flechtner-Mors M, Ditschuneit HH, Johnson TD, et al. Metabolic and weight loss effects of long-term dietary intervention in obese patients: four year results. Obes Res. 2000;8:399–402.
Fabricatore AN. Behavioral therapy and cognitive behavioral therapy of obesity: is there a difference? J Am Diet Assoc. 2007;107:92–9.
Foster GD, Wadden TA, Vogt RA, et al. What is reasonable weight loss? Patient’s expectations and evaluations of obesity treatment outcomes. J Consult Clin Psychol. 1997;65:79–85.
The Diabetes Prevention Research Group. Achieving weight and activity among diabetes prevention program lifestyle participants. Obes Res. 2004;12:1426–34.
The Diabetes Prevention Program Research Group. Description of lifestyle intervention. Diabetes Care. 2002;346:393–403.
Perri MG, Nezu AM, Mckelvey WF, et al. Relapse prevention training and problem-solving therapy in long-term management of obesity. J Consult Clin Psychol. 2001;69:722–6.
The Look AHEAD Research Group. The Look AHEAD Study; a description of lifestyle intervention and the evidence supporting it. Obesity. 2006;14:737–52.
Wadden TA, Butryn MI, Byrne KJ, et al. Efficacy of lifestyle modification for long-term weight control. Obes Res. 2004;12:151S–61.
Tsushima WT, Brindenstine MP, Balfour JF. MMPI-2 scores in the outcome prediction of gastric bypass surgery. Obes Surg. 2004;14:528–32.
Clark MM, Balsiger BM, Sletten CD, et al. Psychosocial factors and 2-year outcomes following Bariatric surgery for weight loss. Obes Surg. 2003;13:739–45.
Hsu LK, Benotti PN, Dwyer J, et al. Nonsurgical factors that influence outcomes of Bariatric surgery: a review. Psychosom Med. 1998;60:338–46.
Green AE, Dymek-Valentine M, Ptluk S, le Grange D, Alverdy J. Psychosocial outcomes of gastric bypass surgery for patients with and without binge eating. Obes Surg. 2004;14:975–85.
Shaw KA, O-Rourke P, Del Mar C, Kennedy J. Psychological interventions for overweight or obesity (review). Cochrane Lib. 2009;1:1–75.
Editors and Affiliations
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
DeLegge, M., Keith, J.N. (2013). Medical Weight Management. In: Thompson, C. (eds) Bariatric Endoscopy. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-1710-2_3
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-1709-6
Online ISBN: 978-1-4419-1710-2